New aspects in the palliative treatment of metastatic colorectal carcinoma;Neuere aspekte in der palliativen behandlung des metastasierten kolorektalen karzinoms

Medizinische Klinik

Volumn 96, Issue 9, 2001, Pages 521-528

  Nolte, Wilhelm ^b   Ramadori, Giuliano ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NONE

Author keywords

5 fluorouracil; Colorectal carcinoma; Irinotecan; Oral prodrugs; Oxaliplatin; Palliative chemotherapy

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PRODRUG; RALTITREXED; UFT;

CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG COST; DRUG INDUCED DISEASE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

BIKINIA LE-TESTUI;

EID: 0035883945     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002237     Document Type: Review

References (78)

1. Perkutane behandlung von lebertumoren durch interstitielle radio-frequenz-thennoablation. Eine neue therapeutische strategie
2. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolos and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
3. Cancer undefeated
4. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening
5. Resection of nonresectable liver metastases from colorectal cancer after neo-adjuvant chemotherapy
6. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial
7. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
8. Colon cancer screening
9. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis
10. Randomized comparative study of ORZEL (oral uracil/tegafur UTF) plus leukovorin (LV) versus parental 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
11. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
12. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
13. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis
14. A phase III trial (SO15695) of Xeloda (capecitabine) in previously untreated advanced metastatic colorectal cancer
15. Final results of a randomised trial comparing 'Tomudex®' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
16. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
17. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study
18. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
19. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
20. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
21. Adjuvant chemotherapy in colorectal carcinoma. Results of a meta-analysis
22. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
23. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Analysis of 1001 consecutive cases
24. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development
25. Phase III multicenter randomized trial of oxaliplatin added to chrono-modulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
26. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer
27. Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer
28. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
29. Sonographisch gesteuerte perkutane hochfrequenzthermotherapie von lebertumoren mit perfundierten nadelelektroden
30. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings
31. Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations
32. Chemoprevention of colorectal cancer
33. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma
34. Die operationsmethodik bestimmt die rezidivhäufigkeit colorectaler carcinome
35. Effective surgical adjuvant therapy for high-risk rectal carcinoma
36. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study
37. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (Leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
38. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
39. Use of colonoscopy to screen asymptomatic adults for colorectal cancer
40. Dissens über den standard bei der adjuvanteu behandlung von kolonkarzinomen
41. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma
42. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
43. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
44. The effect of fecal occult-blood screening on the incidence of colorectal cancer
45. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer
46. Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma
47. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer
48. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
49. Chemotherapy for advanced colorectal cancer. It can improve quality of care and offer modest increases in survival
50. Colorectal cancer
51. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Long-term results
52. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial
53. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
54. Going the distance - The case for true colorectal-cancer screening
55. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial
56. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer
57. Evaluation of ultrasonographic imaging in laser induced thermotherapy in the liver
58. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
59. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
60. Glutamine for irinotecan diarrhea
61. Improved survival with preoperative radiotherapy in resectable rectal cancer
62. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
63. Surgical and multimodality treatment of colorectal liver metastases
64. Arbiter
65. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
66. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer
67. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
68. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
69. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer
70. A phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced metastatic colorectal cancer
71. Raltitrexed (Tomudex™) in combination treatment for colorectal cancer: New perspectives
72. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
73. Magnetresonanztomographisch gesteuerte laserinduzierte thermotherapie von lebermetastasen
74. A randomized phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carcinoma
75. Successful neoadjuvant chemotherapy of nonresectable colorectal liver metastases: An interdisciplinary approach
76. Ultrasound (US) controlled laser-induced interstitial thermotherapy (LITT) for hepatic metastases
77. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National surgical adjuvant breast and bowel project protocol R-02